Genmab opens the weekend with a clear strategy focus, shares hold their biotech range

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 14:43.

Genmab (DK0010272202) starts the weekend with a steady chart on NASDAQ and a clear focus on monoclonal antibody innovation. The biotechnology group’s American Depositary Shares closed at 26.12 US dollars on June 26 on NASDAQ, within a well-defined trading range according to TradingKey.

What recent data and ratings show

Genmab’s stock price currently trades between a cited resistance level at 27.59 dollars and support at 24.14 dollars, a corridor that technical analysts describe as suitable for range-bound swing trading. Based on moving averages and other indicators, TradingKey flags a short-term sell signal, with Genmab showing zero buy and one sell signal on its primary technical dashboard.

On the fundamental and news side, Genmab has highlighted updated clinical data for its bispecific antibody epcoritamab in diffuse large B-cell lymphoma (DLBCL) in elderly patients earlier in June. Finanzen100 reports that the company presented promising response rates from epcoritamab monotherapy and combination regimens in newly diagnosed elderly DLBCL, adding clinical depth to the pipeline story.

Analyst interest and peer comparison

Finanzen100 lists Genmab in the biotechnology sector, referencing a Truist research note that assigns a Buy rating to Genmab shares, underlining continuing analyst interest in the stock. Truist’s stance places the Danish group alongside other antibody-focused peers in the global biotech arena, even as short-term technical indicators remain cautious.

With a market capitalization around 16.17 billion dollars for the NASDAQ-listed Genmab A/S shares, as quoted by TradingKey, the company sits in the mid-to-large cap bracket within biotechnology and medical research. The momentum score of 8.87, ranking 124 out of 387 industry names on TradingKey’s scale, suggests Genmab’s performance is solid but not at the very top of its peer group on a pure price-momentum basis.

The product behind the stock

Genmab’s core business centers on developing and commercializing antibody-based therapeutics for cancer and other serious diseases, with epcoritamab representing a key bispecific antibody program in lymphoma. The company collaborates with larger pharmaceutical partners to advance and market several of its products, creating a mix of proprietary and partnered revenue streams.

Where the stock trades today

The Genmab shares (DK0010272202) trade in the United States on NASDAQ under the ticker GMAB, with a closing price of 26.12 US dollars as of 2026-06-26, 16:00 Eastern Time.

Disclaimer: This article provides factual information on the Genmab stock and does not contain investment advice, buy or sell recommendations, or price targets. All data are based on sources cited in the text and may change over time.